Why There Isn’t a One-Size-Fits-All Plan for States to Reopen Their Economies (The Conversation, Q&A with Hilary Godwin)

In this Q&A, Hilary Godwin, dean of the University of Washington School of Public Health, explains why it makes sense for groups of states, such as Washington, Oregon and California, to coordinate their plans.

Governors are walking a tightrope as they try to figure out how to safely ease off social distancing restrictions and restart their economies without triggering a new surge in coronavirus cases.

Africa Needs Afrocentric Solutions to Beat COVID-19 (Seattle Times - Written by Kingsley Ndoh)

While the U.S. and Europe battle to slow the spread of the novel coronavirus, I can’t help but think about how Africa will cope when it becomes the next epicenter. Based on the three-month-old data that we have about the virus and its spread, guidelines on prevention, containment and mitigation have been set by the World Health Organization (WHO). So far, several African governments have adopted the U.S. and European approach that is centered on lockdowns, social distancing and frequent hand washing with soap and water.

Senior Community Protected in 'Outbreak that Didn’t Happen' (Study led by Alison Roxby)

Newly reported research findings may help in detecting and preventing the spread of COVID19 at independent and assisted living community for senior adults.

One of the valuable lessons from the study at an affected retirement center in Seattle:  Health-professionals should not rely solely on symptoms to determine if an older adult should receive a lab test for the coronavirus.

Now is the Time for a National Public Health Reserve (The Hill - Co-Authored by Alison Drake)

Even before the COVID-19 pandemic, health departments had limited staff, resources and time to support the diverse public health needs of our communities. This system will be further strained as the epidemic grows. We must immediately create a national public health reserve to shore up public health systems. 

First Vaccine Trial for SARS-CoV-2 (includes Rhea Coler)

The Coler Lab at Seattle Children’s Research Institute is using their expertise to support the clinical trial of an experimental coronavirus vaccine funded by National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health. The trial is being conducted at the Kaiser Permanente Washington Health Research Institute in Seattle, part of NIAID’s Infectious Diseases Clinical Research Consortium.

Pages